Yun Zeng

Ms. Yun Zeng


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2022 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
YSYunyan Sun
Yunyan Sun
TWTi-Er Wang
Ti-Er Wang
QHQianwen Hu
Qianwen Hu
WZWenxia Zhang
Wenxia Zhang
YZYun Zeng
Yun Zeng
MSMingxia Shi
Mingxia Shi
Background: Human amniotic mesenchymal stem cells (hAMSCs) are splendid cell sources for clinical application in the administration of numerous refractory and relapse diseases. Despite the preferable prospect of serum-free (SF) condition for cell product standardization and pathogenic contamination remission, yet the systematic and detailed impact upon hAMSCs at both cellular and transcriptomic levels is largely obscure. Methods: For the purpose, we preconditioned hAMSCs under serum-containing (SC) and SF medium for 48 h and compared the biological signatures and biofunctions from the view of cell morphology, immunophenotypes, multi-lineage differentiation in vitro, cell vitality, cytokine expression, and immunosuppressive effect upon the subpopulations of T lymphocytes, together with the PI3K-AKT-mTOR signaling reactivation upon cell vitality. Meanwhile, we took advantage of RNA-SEQ and bioinformatic analyses to verify the gene expression profiling and genetic variation spectrum in the indicated hAMSCs. Results: Compared with those maintained in SC medium, hAMSCs pretreated in SF conditions manifested conservation in cell morphology, immunophenotypes, adipogenic differentiation, and immunosuppressive effect upon the proliferation and activation of most of the T cell subpopulations, but with evaluated cytokine expression (e.g., TGF-β1, IDO1, NOS2) and declined osteogenic differentiation and cell proliferation as well as proapoptotic and apoptotic cells. The declined proliferation in the SF group was efficiently rescued by PI3K-AKT-mTOR signaling reactivation. Notably, hAMSCs cultured in SF and SC conditions revealed similarities in gene expression profiling and variations in genetic mutation at the transcriptome level. Instead, based on the differentially expressed genes and variable shear event analyses, we found those genes were mainly involved in DNA synthesis-, protein metabolism-, and cell vitality-associated biological processes and signaling pathways (e.g., P53, KRAS, PI3K-Akt-mTOR). Conclusions: Collectively, our data revealed the multifaceted cellular and molecular properties of hAMSCs under SC and SF conditions, which suggested the feasibility of serum-free culture for the preferable preparation of standardized cell products for hAMSC drug development and clinical application.

28 July 2021 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
KWKun Wu
Kun Wu
CGChong Guo
Chong Guo
YLYixun Li
Yixun Li
JYJinrong Yang
Jinrong Yang
QZQiang Zhou
Qiang Zhou
YZYun Zeng
Yun Zeng
The Warburg effect is involved in drug resistance and recurrence of cancer, and poses a challenge for the treatment of chronic myelogenous leukemia (CML). Hypoxia‑inducible factor 1α (HIF‑1α) plays a key role in the Warburg effect. microRNAs (miRs) targeting HIF‑1α have potential of regulating such aberrant metabolic process. The present study demonstrated that miR‑18a‑5p was expressed at a low level in K562/ADM cells via reverse transcription‑quantitative PCR (RT‑qPCR). The results of the luciferase reporter assay indicated that miR‑18a‑5p could specifically bind the 3'‑untranslated region of HIF‑1α. Through RT‑qPCR and western blotting, it was revealed that miR‑18a‑5p downregulated the expression of HIF‑1α. By inhibiting HIF‑1α, miR‑18a‑5p suppressed aerobic glycolysis in K562/ADM cells, according to the results produced by glucose uptake, lactate production, pyruvate level and ATP synthesis measurement, along with the results obtained from extracellular acidification rate and oxygen consumption rate assays. These results provided new evidence that miR‑18a‑5p may suppress the Warburg effect by targeting HIF‑1α. Furthermore, via CCK‑8 and flow cytometry assays, cells transfected with miR‑18a‑5p mimics were more sensitive to Adriamycin (AMD) compared with AMD group. Reversing the Warburg effect by miR‑30a‑5p might provide a potential therapeutic strategy for CML.

10 April 2025 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
JYJinrong Yang
Jinrong Yang
ZWZixu Wang
Zixu Wang
KWKun Wu
Kun Wu
JRJingyan Ruan
Jingyan Ruan
BNBo Nie
Bo Nie
YZYun Zeng
Yun Zeng
Metabolic abnormalities have been identified in various solid tumors and hematologic diseases, with reprogramming of central carbon metabolism occurring to promote disease progression. However, the metabolic profile of central carbon in acute myeloid leukemia (AML) remains unknown. We employed targeted metabolomics to analyze the alterations in central carbon metabolites present in the blood of acute myeloid leukemia (AML) patients. Models constructed using orthogonal partial least squares discriminant analysis (OPLS-DA) were utilized to evaluate intergroup differences in metabolite levels. Furthermore, a public database facilitated the kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis. Additionally, metabolites exhibiting significant differences were selected, and their effects on the proliferation and drug resistance of human myeloid leukemia cell lines were validated in vitro using CCK-8 analysis, MTT assays, and flow cytometry. Our results indicated that 27 targeted metabolites were up-regulated and eight targeted metabolites were down-regulated in the AML group. These metabolites were primarily enriched in pathways related to the biosynthesis of cofactors, glyoxylate and dicarboxylate metabolism, glucagon signaling, 2-oxocarboxylic acid metabolism, biosynthesis of amino acids, the citrate cycle (TCA cycle), and central carbon metabolism in cancer. Notably, significant changes were observed in malic acid, alpha-ketoisovaleric acid, and glucuronic acid. In vitro experiments demonstrated that exogenous glucuronic acid can promote the growth and drug resistance of human AML cells. In conclusion, this study reveals alterations in central carbon metabolites in the blood of AML patients and identifies metabolites that may play a role in AML development and drug resistance.

1 October 2021 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
KWKun Wu
Kun Wu
BNBo Nie
Bo Nie
LLLiyin Li
Liyin Li
XYXin Yang
Xin Yang
JYJinrong Yang
Jinrong Yang
YZYun Zeng
Yun Zeng
Background: Myelodysplastic syndrome (MDS) is a group of hematological malignancies that may progress to acute myeloid leukemia (AML). Bioinformatics-based analysis of high-frequency mutation genes in MDS-related patients is still relatively rare, so we conducted our research to explore whether high-frequency mutation genes in MDS-related patients can play a reference role in clinical guidance and prognosis. Methods: Next generation sequencing (NGS) technology was used to detect 32 mutations in 64 MDS-related patients. We classified the patients’ genes and analyzed them by Gene Ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, protein-protein interaction (PPI) analysis, and then calculated the gene survival curve of high-frequency mutations. Results: We discovered 32 mutant genes such as ASXL1, DNMT3A, KRAS, NRAS, TP53, SF3B1, and SRSF2. The overall survival (OS) of these genes decreased significantly after DNMT3A, ASXL1, RUNX1, and U2AF1 occurred mutation. These genes play a significant role in biological processes, not only in MDS but also in the occurrence and development of other diseases. Through retrospective analysis, genes associated with MDS-related diseases were identified, and their effects on the disease were predicted. Conclusions: Thirty-two mutant genes were determined in MDS and when mutations occur in DNMT3A, ASXL1, RUNX1, and U2AF1, their survival time decreases significantly. This results providing a theoretical basis for clinical and scientific research and broadening the scope of research on MDS.

12 May 2025 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
HCHuacong Cai
Huacong Cai
JWJishi Wang
Jishi Wang
ZYZhenyu Yan
Zhenyu Yan
HZHu Zhou
Hu Zhou
ZLZhenyu Li
Zhenyu Li
SWShujie Wang
Shujie Wang
A novel, highly purified 10% intravenous immunoglobulin (IVIG) formulation was evaluated for both therapeutic efficacy and safety profile in adult patients diagnosed with persistent or chronic primary immune thrombocytopenia (ITP). This phase III, multicenter, open-label, single-arm clinical trial enrolled Chinese adult patients diagnosed with persistent or chronic ITP presenting with baseline platelet counts below 30 × 109/L. Participants received intravenous administration of 10% IVIG at a standardized dosage of 1 g/kg/day for two consecutive days. The primary efficacy endpoint was defined as the proportion of subjects achieving both a platelet count elevation to ≥ 30 × 109/L and a minimum two-fold increase from baseline values within a 7-day post-treatment observation period following the first dose administration. Seventy-two patients were enrolled and sixty patients completed the study. 52 (72.2%; 95% CI: 60.4, 82.1) patients achieved platelet count ≥ 30 × 109/L and experienced a ≥ twofold increase from baseline within 7 days, and 52 (72.2%; 95% CI: 60.4, 82.1) patients achieved complete response (CR) or response (R) within 7 days. 64 patients (88.9%; 95% CI: 79.3, 95.1) achieved platelet count ≥ 50 × 109/L within 7 days with a median time of 3 days. 71 patients completed the ITP bleeding scale assessment after 7 days, showing a decrease of 0.6 ± 1.07 from baseline. A total of 66 patients (91.7%) reported treatment-emergent adverse events (TEAEs) during the study, and 37 patients (51.4%) reported adverse drug reactions (ADRs). The most prevalent ADRs with an incidence exceeding 5% included headache (n = 12, 16.7%), fever (n = 10, 13.9%), decreased white blood cell count (n = 5, 6.9%), and nausea (n = 5, 6.9%). The therapeutic regimen of 10% IVIG administered at a dosage of 1 g/kg/day for two consecutive days demonstrated both favorable safety profiles and clinical efficacy. These robust findings provide substantial evidence supporting the clinical application of this novel 10% IVIG formulation in the management of adult patients with ITP.

11 November 2024 in Hematological Oncology
Verified
Journal Article
Open access
JYJinrong Yang
Jinrong Yang
ZWZixu Wang
Zixu Wang
KWKun Wu
Kun Wu
BNBo Nie
Bo Nie
LLLiyin Li
Liyin Li
MSMingxia Shi
Mingxia Shi
Mutation of isocitrate dehydrogenase 2 (IDH2) is a key factor in promoting cytarabine (Ara‐C) resistance in acute myeloid leukemia (AML), however the underly mechanism remains unclear. Acute myeloid leukemia cells, were cultured with either IDH2 knockdown (KD‐IDH2) or overexpression (OE‐IDH2) to elucidate the role of IDH2 in these leukemic cell lines. Additionally, mutant cell lines were engineered to replicate clinically relevant IDH2 mutations. To investigate cellular responses, the glycolytic inhibitor 2‐deoxy‐D‐glucose (2‐DG) was administered to the cells. Cell proliferation was quantified using a Cell Counting Kit‐8 (CCK‐8), while apoptosis was evaluated through propidium iodide staining followed by flow cytometry. Glycolytic metabolism levels were measured using a specific reagent kit, and Western blotting was employed to determine the expression levels of glycolysis‐related proteins. Transcriptome sequencing was conducted to elucidate the mechanisms by which IDH2 mutations influence glycolysis. Furthermore, both in vitro cell experiments and in vivo subcutaneous transplantation tumor models in nude mice were utilized to validate these mechanisms. OE‐IDH2 in AML cells, enhances resistance to the Ara‐C, promotes cell proliferation and glycolysis, and inhibits apoptosis. KD‐IDH2 exhibits opposite effects. Both IDH2 mutations and OE‐IDH2 produce similar effects on these cellular processes. The increase in glycolysis levels following IDH2 mutation may contribute to the reduced efficacy of Enasidenib in inhibiting the proliferation of IDH‐mutant AML cells. Transcriptome sequencing results indicate an enrichment of the PI3K/Akt signaling pathway in IDH2‐mutant AML cells. BEZ235 significantly inhibits the expression of phosphorylated PI3K (p‐PI3K), phosphorylated Akt (p‐Akt), mTOR, glycolytic metabolism, and Ara‐C resistance both in vitro and in vivo. Overexpression and mutation of IDH2 coordinate with the Warburg effect through the PI3K/Akt/mTOR pathway to promote Ara‐C resistance in AML.